©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Sep 25, 2025; 14(3): 103347
Published online Sep 25, 2025. doi: 10.5501/wjv.v14.i3.103347
Published online Sep 25, 2025. doi: 10.5501/wjv.v14.i3.103347
Chronic hepatitis B: Is it time for expanded antiviral treatment?
Manish Manrai, Atul A Jha, Department of Gastroenterology, Command Hospital, Lucknow 226002, Uttar Pradesh, India
Aditya V Pachisia, Department of Gastroenterology, Command Hospital, Bangalore 560007, Karnataka, India
Saurabh Dawra, Department of Gastroenterology, Command Hospital, Udhampur 182101, Jammu and Kashmīr, India
Author contributions: Manrai M conceptualized, supervised the review study, and was involved with resources, editing, and validation; Jha AA was involved with resources and writing; Pachisia AV was involved in resources, writing, and editing; Dawra S was involved with resources and writing.
Conflict-of-interest statement: There is no conflict of interest.
Corresponding author: Manish Manrai, Professor, Department of Gastroenterology, Command Hospital, Lucknow Cantt, Lucknow 226002, Uttar Pradesh, India. manishmanrai75@gmail.com
Received: November 18, 2024
Revised: May 1, 2025
Accepted: July 11, 2025
Published online: September 25, 2025
Processing time: 313 Days and 16.3 Hours
Revised: May 1, 2025
Accepted: July 11, 2025
Published online: September 25, 2025
Processing time: 313 Days and 16.3 Hours
Core Tip
Core Tip: An estimated 254 million people, almost 3.3% of the world's population, are estimated to be living with chronic hepatitis B infection. Without therapy, they are at risk of developing cirrhosis and may develop hepatocellular cancer. The prevention of hepatocellular carcinoma is a major challenge. We review the various clinical practice guidelines and consider emerging evidence that will foster research to consider the expansion of treatment indications of chronic hepatitis B.